Wamberg Genomic Advisors Announces The Penn Mutual Life Insurance Company to Provide Cancer Guardian as a Benefit to its Associates
LA JOLLA, Calif., Sept. 12, 2018
LA JOLLA, Calif., Sept. 12, 2018 /PRNewswire/ -- Wamberg Genomic Advisors announced that The Penn Mutual Life Insurance Company (Penn Mutual) will be providing the Cancer Guardian™ program to its associates, plus their spouses and dependents starting on October 1st. Since 1847, Penn Mutual has been committed to helping people live life with confidence. At the heart of this purpose is the belief that life insurance is central to a sound financial plan. Their network of trusted advisers is dedicated to helping individuals, families and businesses achieve their dreams. Penn Mutual engaged Pentra, LLC, An Alera Group company to assist in the evaluation of the Cancer Guardian program.
Cancer Guardian is a program that provides guidance, resources and access to leading-edge DNA testing at the time of a cancer diagnosis. Wamberg recently announced enhancements to Cancer Guardian to now include expanded Comprehensive Cancer Support.
According to David O'Malley, president and chief operating officer of The Penn Mutual Life Insurance Company, "Penn Mutual's greatest strength is its people. Cancer can impact anyone, and the Cancer Guardian program further strengthens our commitment to our associates at times when they need it the most."
Added Tom Wamberg, president & CEO of Wamberg Genomic Advisors, "With this program, Penn Mutual is clearly deepening the bond with their greatest asset – associates. Individuals empowered with a host of resources, and access to advanced genetic testing are better equipped to navigate through a critical life event, such as cancer. Additionally, knowledge of a person's genome is enabling medical professionals to develop personalized health strategies, treatments, and care paths when needed."
About Pentra, LLC, An Alera Group Company
Alera combines national resources and local delivery to deliver the best possible outcomes for clients—positively impacting our employees, clients, communities and the lives of people where we serve. With over 1,000 employees serving thousands of clients in employee benefits, property and casualty, risk management and wealth management, Alera Group is the 15th largest independent insurance agency and the 7th largest independent employee benefits firm in the country. For more information, visit www.pentra.com and www.aleragroup.com.
About The Penn Mutual Life Insurance Company
Since 1847, Penn Mutual has been committed to helping people live life with confidence. At the heart of this purpose is the belief that life insurance is central to a sound financial plan. Through our network of trusted advisers, we are dedicated to helping individuals, families and businesses achieve their dreams. Penn Mutual supports its advisers with retirement and investment services through Hornor, Townsend & Kent, Inc. Registered Investment Advisor and wholly owned subsidiary. Member FINRA/SIPC. We are proud to work together in a values-driven and relationship-based culture. Visit Penn Mutual at www.pennmutual.com.
About Wamberg Genomic Advisors
Wamberg Genomic Advisors is the first company dedicated to making genomic based programs and services available at prices everyone can afford. Advanced DNA testing can provide insights to individuals and healthcare providers for better-informed decisions about overall health, patient care paths and the quality and longevity of life. Wamberg Genomic Advisors delivers genomic products and services to employers and their employees via their trusted benefit brokers, and to policyholders of life insurance companies through qualified agents. To discover more about Wamberg Genomic Advisors and the future of genomics, visit wamberggenomic.com and cancerguardian.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/wamberg-genomic-advisors-announces-the-penn-mutual-life-insurance-company-to-provide-cancer-guardian-as-a-benefit-to-its-associates-300711103.html
SOURCE Wamberg Genomic Advisors